abnormal bone mineralization_Tnfrsf11a<tm1Kost>/Tnfrsf11a<tm1Kost>

http://metadb.riken.jp/0002896I129SvBlackSwissTnfrsf11atm1KostTnfrsf11atm1KostTnfrsf11atm1Kost

abnormal bone mineralization_Tnfrsf11a<tm1Kost>/Tnfrsf11a<tm1Kost>

表現型アノテーション

MGI marker

http://metadb.riken.jp/db/mgi_rdf/variant_of

• tumor necrosis factor receptor superfamily, member 11a, NFKB activator
  http://metadb.riken.jp/db/mgi_rdf/MGI:1314891

遺伝子型

http://metadb.riken.jp/db/mgi_rdf/allele_composition

• Tnfrsf11a<tm1Kost>/Tnfrsf11a<tm1Kost>

アレルシンボル

http://metadb.riken.jp/db/mgi_rdf/allele_symbol

• Tnfrsf11a<tm1Kost>

遺伝的背景

http://metadb.riken.jp/db/mgi_rdf/genetic_background

• involves: 129/Sv * Black Swiss

MP annotation

http://metadb.riken.jp/db/bioresource_schema/brs_indicatesPhenotype

• abnormal bone mineralization
  http://purl.obolibrary.org/obo/MP_0002896

文献

http://purl.org/net/cito/citesAsAuthority

• Paul J. Kostenuik, et.al., Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL., Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2009, 24
  http://rdf.ncbi.nlm.nih.gov/pubmed/19016581